Glucagon-like peptide-2 exhibits protective effect on hepatic ischemia-reperfusion injury in rats

详细信息    查看全文

• 作者：Naci Topalo?lu ; Adem Kü?ük ; ?ule Y?ld?r?m ; Mustafa Tekin…
• 关键词：ischemia/reperfusion ; liver ; glucagon ; like peptide ; 2 ; alanine aminotransferase
• 刊名：Frontiers of Medicine
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：9
• 期：3
• 页码：368-373
• 全文大小：370 KB
• 参考文献：1.Abu-Amara M, Yang SY, Tapuria N, Fuller B, Davidson B, Seifalian A. Liver ischemia/reperfusion injury: processes in inflammatory networks—a review. Liver Transpl 2010; 16(9): 1016-032CrossRef PubMed
  2.Taki-Eldin A, Zhou L, Xie HY, Chen KJ, Yu D, He Y, Zheng SS. Triiodothyronine attenuates hepatic ischemia/reperfusion injury in a partial hepatectomy model through inhibition of proinflammatory cytokines, transcription factors, and adhesion molecules. J Surg Res 2012; 178(2): 646-56CrossRef PubMed
  3.Rushing GD, Britt LD. Reperfusion injury after hemorrhage: a collective review. Ann Surg 2008; 247(6): 929-37CrossRef PubMed
  4.Birrer R, Takuda Y, Takara T. Hypoxic hepatopathy: pathophysiology and prognosis. Intern Med 2007; 46(14): 1063-070CrossRef PubMed
  5.Tapuria N, Kumar Y, Habib MM, Abu Amara M, Seifalian AM, Davidson BR. Remote ischemic preconditioning: a novel protective method from ischemia reperfusion injury—a review. J Surg Res 2008; 150(2): 304-30CrossRef PubMed
  6.Kandilci HB, Gümüsel B. Ischemia-reperfusion injury and ischemic preconditioning in lungs. Hacettepe University Journal of the Faculty of Pharmacy 2005; 25: 35-9 (in Turkish)
  7.Kaplowitz N. Mechanisms of liver cell injury. J Hepatol 2000; 32(1 Suppl): 39-7CrossRef PubMed
  8.Jaeschke H. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. Am J Physiol Gastrointest Liver Physiol 2003; 284(1): G15–G26CrossRef PubMed
  9.Teoh NC, Farrell GC. Hepatic ischemia reperfusion injury: pathogenic mechanisms and basis for hepatoprotection. J Gastroenterol Hepatol 2003; 18(8): 891-02CrossRef PubMed
  10.Guan X, Karpen HE, Stephens J, Bukowski JT, Niu S, Zhang G, Stoll B, Finegold MJ, Holst JJ, Hadsell D, Nichols BL, Burrin DG. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 2006; 130(1): 150-64CrossRef PubMed
  11.Bremholm L, Hornum M, Henriksen BM, Larsen S, Holst JJ. Glucagon-like peptide-2 increases mesenteric blood flow in humans. Scand J Gastroenterol 2009; 44(3): 314-19CrossRef PubMed
  12.Bremholm L, Hornum M, Andersen UB, Hartmann B, Holst JJ, Jeppesen PB. The effect of glucagon-like peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients. Regul Pept 2011; 168(1-): 32-8CrossRef PubMed
  13.Deniz M, Bozkurt A, Kurtel H. Mediators of glucagon-like peptide 2-induced blood flow: responses in different vascular sites. Regul Pept 2007; 142(1-): 7-5CrossRef PubMed
  14.Benjamin MA, McKay DM, Yang PC, Cameron H, Perdue MH. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 2000; 47(1): 112-19CrossRef PubMed Central PubMed
  15.Cani PD, Possemiers S, Van deWiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58(8): 1091-103CrossRef PubMed Central PubMed
  16.Ivory CP, Wallace LE, McCafferty DM, Sigalet DL. Interleukin-10- independent anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 2008; 295(6): G1202–G1210CrossRef PubMed
  17.Sigalet DL, Wallace LE, Holst JJ, Martin GR, Kaji T, Tanaka H, Sharkey KA. Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 2007; 293(1): G211–G221CrossRef PubMed
  18.Munroe DG, Gupta AK, Kooshesh F, Vyas TB, Rizkalla G, Wang H, Demchyshyn L, Yang ZJ, Kamboj RK, Chen H, McCallum K, Sumner-Smith M, Drucker DJ, Crivici A. Prototypic G proteincoupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA 1999; 96(4): 1569-573CrossRef PubMed Central PubMed
  19.Thulesen J, Hartmann B, ?rskov C, Jeppesen PB, Holst JJ, Poulsen SS. Potential targets for glucagon-like peptide 2 (GLP-2) in the rat: distribution and binding of i.v. injected (125)I-GLP-2. Peptides 2000; 21(10): 1511-517CrossRef PubMed
  20.Chiappa AC, Makuuchi M, Zbar AP, Biella F, Vezzoni A, Torzilli G, Andreoni B. Protective effect of methylprednisolone and of intermittent hepatic pedicle clamping during liver vascular inflow occlusion in the rat. Hepatogastroenterology 2004; 51(59): 1439-444PubMed
  21.Aslan A, Karagüzel G, Celik M, Uysal N, Yücel G, Melikoglu M. Pentoxifylline contributes to the hepatic cytoprotective process in rats undergoing hepatic ischemia and reperfusion injury. Eur Surg Res 2001; 33(4): 285-90CrossRef PubMed
  22.Portakal O, Inal-Erden M. Effects of pentoxifylline and coenzyme Q10 in hepatic ischemia/reperfusion injury. Clin Biochem 1999; 32(6): 461-66CrossRef PubMed
  23.Vardareli E, Saricam T, Koken T, Degirmenci I, Aral E, Erenoglu E. The effect of alpha-tocoph
• 作者单位：Naci Topalo?lu (1)
  Adem Kü?ük (2)
  ?ule Y?ld?r?m (1)
  Mustafa Tekin (1)
  Havva Erdem (3)
  Mustafa Deniz (4)
  
  1. Medical Faculty, Department of Pediatrics, ?anakkale Onsekiz Mart University, ?anakkale, Turkey
  2. Department of Pediatric Surgery, Düzce Atatürk State Hospital, Düzce, Turkey
  3. Medical Faculty, Department of Pathology, Düzce University, Düzce, Turkey
  4. Medical Faculty, Department of Physiology, ?anakkale Onsekiz Mart University, ?anakkale, Turkey
  
• 刊物主题：Medicine/Public Health, general;
• 出版者：Springer Berlin Heidelberg
• ISSN：2095-0225

文摘

Glucagon-like peptide-2 (GLP-2) has potent anti-inflammatory effects and protects against experimental ischemia/reperfusion (I/R) injury in pulmonary, intestinal, and myocardial tissue. However, its protective abilities against I/R injury in the liver are unknown. We investigated the potential role of GLP-2 pretreatment on hepatic I/R injury in rats. A total of 24 rats were randomly divided into three groups (n = 8). The first group was the control group; the second group was the vehicle-treated hepatic ischemia/reperfusion (HIR, vehicle saline-treated) group; and the third group was the GLP-2 pretreated I/R (GLP2-IR) group. Each rat in the third group was intraperitoneally administered 5 μg GLP-2 for 5 d before the procedure. A portal triad was created to induce ischemia with a vascular atraumatic clamp. After 40 min, the clamp was released to initiate hepatic reperfusion for 6 h. Blood samples and tissue specimens from the liver were obtained. Alanine aminotransferase, aspartate aminotransferase, and total bilirubin levels significantly increased in the salinetreated HIR group (P < 0.001), whereas GLP-2 pretreatment significantly decreased their levels (P < 0.01). Our data suggested that GLP-2 pretreatment may have a protective effect on liver I/R injury. However, dose-response studies are necessary to determine the most effective dose. Keywords ischemia/reperfusion liver glucagon-like peptide-2 alanine aminotransferase